Equities

Champions Oncology Inc

Champions Oncology Inc

Actions
Health CareHealth Care Providers
  • Price (USD)4.77
  • Today's Change-0.12 / -2.45%
  • Shares traded33.09k
  • 1 Year change-10.84%
  • Beta0.4541
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.

  • Revenue in USD (TTM)51.66m
  • Net income in USD-3.40m
  • Incorporated1985
  • Employees210.00
  • Location
    Champions Oncology IncOne University Plaza,, Suite 307HACKENSACK 07601United StatesUSA
  • Phone+1 (201) 808-8400
  • Fax+1 (302) 636-5454
  • Websitehttps://championsoncology.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bioqual Inc62.86m957.02k60.37m108.0063.081.5517.210.96041.071.0770.2843.411.04--2.99--1.598.141.809.5214.1319.361.527.13----0.0021.43-5.2711.79-84.12-25.261.6010.76
Enzo Biochem Inc33.34m-17.55m60.72m179.00--0.8757--1.82-0.35160.91940.66331.350.40281.664.91186,257.00-21.20-12.21-34.50-15.7943.6637.09-52.63-18.763.16--0.053---4.85-21.01-23.02--7.89--
VolitionRX Ltd976.52k-32.42m60.79m110.00------62.25-0.4032-0.40320.0121-0.2630.0481--5.388,877.45-161.39-111.92---196.20-----3,357.34-10,793.31---129.66----153.04---16.68--29.13--
Vor Biopharma Inc0.00-118.09m61.56m168.00--0.6273-----1.74-1.740.001.430.00----0.00-60.16-45.79-64.52-48.98------------0.00-------27.98------
Kronos Bio Inc8.41m-102.85m62.10m58.00--0.5041--7.38-1.75-1.750.14252.040.0396----135,661.30-48.41-35.47-53.26-37.14-----1,222.83-7,975.76----0.00------15.41---8.78--
Rapt Therapeutics Inc0.00-120.43m62.48m122.00--0.572-----3.12-3.120.003.130.00----0.00-69.23-46.30-75.81-49.97-------3,522.72----0.00---100.00---39.31---20.31--
RetinalGenix Technologies Inc0.00-4.04m62.51m0.00---------0.2291-0.22910.00-0.1010.00-------9,059.05-9,163.75---------------1,050.46--------46.58------
enVVeno Medical Corp0.00-20.60m63.32m31.00--1.65-----1.43-1.430.002.880.00----0.00-56.37-58.43-59.43-62.76-------260,799.30----0.00------4.67--21.58--
Champions Oncology Inc51.66m-3.40m64.84m210.00------1.26-0.2541-0.25413.78-0.02441.88--5.75245,976.20-12.39-10.00-44.43-23.0044.2746.58-6.58-6.04----333.00---6.9013.13-36.38--0.0479--
Celularity Inc22.77m-196.30m65.51m120.00--1.41--2.88-11.29-11.291.302.110.08362.902.39189,758.30-72.04-19.19-94.47-20.9929.66---862.04-454.790.20861.370.4893--26.68---1,483.14------
Connect Biopharma Holdings Ltd (ADR)24.12m-21.25m67.96m81.00--0.6152--2.82-0.3869-0.38690.4362.000.1826----297,728.40-16.09-66.24-17.73-71.36-----88.10------0.0029------49.61--10.32--
Vivani Medical Inc0.00-24.20m67.96m44.00--2.85-----0.4643-0.46430.000.43160.00----0.00-44.89-56.58-50.97-67.66-------2,868.72----0.00-------84.69--40.33--
Maia Biotechnology Inc0.00-28.08m69.09m13.00--21.70-----1.62-1.620.000.13320.00----0.00-251.96---362.21--------------0.00-------21.91------
Precision BioSciences Inc87.64m15.79m69.52m110.00--0.91623.320.7932-0.13630.20217.5910.490.5044--79.03804,036.709.09-35.3512.24-44.22----18.02-147.50----0.2314--94.1534.9641.67---32.01--
OS Therapies Inc0.00-6.55m69.77m4.00---------0.3011-0.30110.00-1.32------0.00-------------------0.9763---------24.09------
Data as of Sep 20 2024. Currency figures normalised to Champions Oncology Inc's reporting currency: US Dollar USD

Institutional shareholders

17.54%Per cent of shares held by top holders
HolderShares% Held
West Elk Capital LLCas of 25 Aug 20231.09m8.04%
Tocqueville Asset Management LPas of 31 Mar 2024684.63k5.04%
Renaissance Technologies LLCas of 30 Jun 2024122.59k0.90%
BlackRock Fund Advisorsas of 31 Mar 2024113.87k0.84%
The Vanguard Group, Inc.as of 31 Mar 202483.51k0.61%
Essex Investment Management Co. LLCas of 31 Mar 202477.20k0.57%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 202469.30k0.51%
Geode Capital Management LLCas of 30 Jun 202463.09k0.46%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 202440.70k0.30%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202436.11k0.27%
More ▼
Data from 08 Oct 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.